

Shane Shapera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/924916/publications.pdf>

Version: 2024-02-01

34
papers

645
citations

623734

14
h-index

610901

24
g-index

34
all docs

34
docs citations

34
times ranked

805
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2022, 161, 1320-1329.	0.8	25
2	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. <i>Respiratory Medicine</i> , 2022, 191, 106722.	2.9	3
3	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. <i>European Respiratory Journal</i> , 2022, 60, 2102571.	6.7	57
4	Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001163.	3.0	7
5	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. <i>Respirology</i> , 2022, 27, 635-644.	2.3	12
6	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. <i>Thorax</i> , 2021, 76, 37-43.	5.6	28
7	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 202.	3.6	5
8	Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. <i>Lung</i> , 2021, 199, 379-387.	3.3	4
9	Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021015.	0.2	0
10	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 25-30.	0.5	0
11	Development of the Functional Assessment of Cancer Therapyâ€œImmune Checkpoint Modulator (FACTâ€œICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	4.1	26
12	Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1362-1378.	1.2	20
13	EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL. <i>Chest</i> , 2020, 158, A2613-A2615.	0.8	0
14	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 147-155.	0.5	3
15	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 226-228.	0.5	2
16	Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 165-173.	0.5	1
17	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. <i>Respiratory Research</i> , 2020, 21, 322.	3.6	18
18	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€œassociated Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1077-1084.	3.2	5

#	ARTICLE	IF	CITATIONS
19	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. <i>Chest</i> , 2020, 158, 1069-1078.	0.8	57
20	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 887-895.	0.8	14
21	Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. <i>Lung</i> , 2019, 197, 277-284.	3.3	17
22	Procedure volume and mortality after surgical lung biopsy in interstitial lung disease. <i>European Respiratory Journal</i> , 2019, 53, 1801164.	6.7	54
23	Diagnostic criteria for idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, e6.	10.7	1
24	Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2018, 153, 1405-1415.	0.8	44
25	Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT). <i>Clinical Lung Cancer</i> , 2018, 19, e219-e226.	2.6	57
26	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 234-243.	0.5	8
27	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2018, 2, 257-258.	0.5	0
28	Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. <i>Respiratory Medicine</i> , 2017, 125, 65-71.	2.9	13
29	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 133-141.	0.5	15
30	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-7.	1.6	45
31	Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 218-225.	5.6	98
32	Diagnostic Disparity of Previous and Revised American Thoracic Society Guidelines for Idiopathic Pulmonary Fibrosis. <i>Canadian Respiratory Journal</i> , 2015, 22, 86-90.	1.6	3
33	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. <i>Canadian Respiratory Journal</i> , 2015, 22, 308-308.	1.6	1
34	What to Do with All of These Lung Nodules?. <i>Canadian Respiratory Journal</i> , 2014, 21, e52-e54.	1.6	2